{"id":464557,"date":"2021-03-24T16:08:22","date_gmt":"2021-03-24T20:08:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=464557"},"modified":"2021-03-24T16:08:22","modified_gmt":"2021-03-24T20:08:22","slug":"clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/","title":{"rendered":"ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">IRVINE, Calif., March  24, 2021  (GLOBE NEWSWIRE) &#8212; ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the \u201cCompany\u201d), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ellisa Cholapranee will join the Company as General Counsel on April 5, 2021. Ms. Cholapranee will report directly to Joe Burnett, ClearPoint Neuro\u2019s Chief Executive Officer, and serve as a member of the Company\u2019s senior leadership team.<\/p>\n<p align=\"justify\">\u201cEllisa is a tremendous addition to our capable and growing leadership team,\u201d commented Joe Burnett, President and CEO of ClearPoint Neuro. \u201cNot only does Ellisa offer the broad experience in compliance, contracting and strategy, but like our Company itself, she has experience in both medical devices and biologics and drug delivery. Her insight having worked extensively as a partner to the pharma industry will enhance communication and efficiency, both in signing new gene therapy and stem cell partners, as well as broaching more sophisticated risk sharing agreements with our collaborators.\u201d<\/p>\n<p align=\"justify\">Ms. Cholapranee brings to the Company almost a decade of experience advising companies in the life science and medical device sectors on legal, business, and compliance issues. Before joining the Company, she was Senior Legal Counsel for the cardiovascular devices division at Philips. Prior to that, Ms. Cholapranee served as Senior Corporate Counsel at MilliporeSigma, a global life science company focused on providing solutions to pharmaceutical companies in every step of the biotech production chain, from research to drug manufacturing. She also has several years\u2019 experience in the corporate and financial services departments of leading law firms in Boston and Chicago, where she counseled clients in the areas of corporate law, public offerings, mergers and acquisitions, and venture capital. Ms. Cholapranee holds a Bachelor of Science in Mathematics from Carnegie Mellon University, and a J.D. from the Northwestern University Pritzker School of Law.<\/p>\n<p align=\"justify\">\u201cI am thrilled to join ClearPoint at such an exciting phase of the Company\u2019s growth,\u201d stated Ellisa Cholapranee. \u201cClearPoint\u2019s technology and team are truly impressive. I look forward to helping build upon the many successes of the Company.\u201d<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>About ClearPoint Neuro<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">ClearPoint Neuro\u2019s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company\u2019s current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active clinical sites in the United States, Canada, and Europe. The Company\u2019s SmartFlow<sup>\u00ae<\/sup> cannula is being used in partnership or evaluation with 25 individual biologics and drug delivery companies in various stages from preclinical research to late-stage regulatory trials. To date, more than 4,000 cases have been performed and supported by the Company\u2019s field-based clinical specialist team which offers support and services for our partners. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gndz6YDb4aj2qth0nzNn2ad0oyD_twO03bJi-8ibhjRssGH8rb4EXN6knyH3rst9jm77TrEatmeUrs66cciB0-Ce4HJTuOdBxJDHktAT1Bg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.clearpointneuro.com<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <u>Forward-Looking Statements<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">Statements herein concerning the Company\u2019s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company&#8217;s future events, developments and future performance, as well as management&#8217;s expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company&#8217;s actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company\u2019s ClearPoint Neuro Navigation System products; and the Company\u2019s ability to market, commercialize and achieve broader market acceptance for the Company\u2019s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company\u2019s actual results are described in the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2020, which has been filed with the Securities and Exchange Commission.<\/p>\n<p><strong>Contact:<\/strong><\/p>\n<p>Jacqueline Keller, Vice President, Marketing<br \/>(949) 900-6833<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mh--7XKbXzHD3JvJoQk72Pgg9Us9Sevdue7ywB6bBTnAACq8nwwPpE0LABByI1znPjpl0frB3XY14JTIZ_fU3bQXn75KMZPuKXad-rWjF7k=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@clearpointneuro.com<\/a><\/p>\n<p>Caroline Corner, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hXR48baIBGAhr5MbwxMD-_9aNvqITITJ7KV_Z0ahTxmPKdKrrjYTTwGSUZSMOAr4u1RFbW8RRc3-pZSomhorYWfWCdzNvm6ol_A_FQSc61Y=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@clearpointneuro.com<\/a><\/p>\n<p align=\"justify\">A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-GOBEoNSSRYtOj87Y-wlITFMDVCOpVTLCJcl7C57RY2COt-t4iNuVE4nKcMtpdiZO2SiHCWfOYUd2JfJQcG3EI8rmkbdoSgva_sKjkSrVDXV7HAH9onWVD6MukG9ZunKISmi58pVVNXL8s5n7uUTzLVinMRmVjy0L0atCMbGc4cqbg8L-lCod1Y22bb0EQSC3k6y5cgsXAdimtAkxlynDhwBeJfSDTe1OgEOx9JYOPyAp33NT46WjkurgLgoMqX9tZmoUi9nWNzt9vKzpMIDuA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/fbcbd8ad-a160-4fd1-ab3f-cdd745f12760<\/a>.<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTI3MiM0MDg4NTg0IzIwMjcxMjA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/6c67f9d0-d7f5-45f3-a4aa-845f6fbd22b3\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>IRVINE, Calif., March 24, 2021 (GLOBE NEWSWIRE) &#8212; ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the \u201cCompany\u201d), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ellisa Cholapranee will join the Company as General Counsel on April 5, 2021. Ms. Cholapranee will report directly to Joe Burnett, ClearPoint Neuro\u2019s Chief Executive Officer, and serve as a member of the Company\u2019s senior leadership team. \u201cEllisa is a tremendous addition to our capable and growing leadership team,\u201d commented Joe Burnett, President and CEO of ClearPoint Neuro. \u201cNot only does Ellisa offer the broad experience in compliance, contracting and strategy, but like our Company itself, she has experience in both medical devices and biologics and drug delivery. Her insight &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-464557","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif., March 24, 2021 (GLOBE NEWSWIRE) &#8212; ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the \u201cCompany\u201d), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ellisa Cholapranee will join the Company as General Counsel on April 5, 2021. Ms. Cholapranee will report directly to Joe Burnett, ClearPoint Neuro\u2019s Chief Executive Officer, and serve as a member of the Company\u2019s senior leadership team. \u201cEllisa is a tremendous addition to our capable and growing leadership team,\u201d commented Joe Burnett, President and CEO of ClearPoint Neuro. \u201cNot only does Ellisa offer the broad experience in compliance, contracting and strategy, but like our Company itself, she has experience in both medical devices and biologics and drug delivery. Her insight &hellip; Continue reading &quot;ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-24T20:08:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTI3MiM0MDg4NTg0IzIwMjcxMjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel\",\"datePublished\":\"2021-03-24T20:08:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\\\/\"},\"wordCount\":714,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTI3MiM0MDg4NTg0IzIwMjcxMjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\\\/\",\"name\":\"ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTI3MiM0MDg4NTg0IzIwMjcxMjA=\",\"datePublished\":\"2021-03-24T20:08:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTI3MiM0MDg4NTg0IzIwMjcxMjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTI3MiM0MDg4NTg0IzIwMjcxMjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/","og_locale":"en_US","og_type":"article","og_title":"ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel - Market Newsdesk","og_description":"IRVINE, Calif., March 24, 2021 (GLOBE NEWSWIRE) &#8212; ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the \u201cCompany\u201d), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ellisa Cholapranee will join the Company as General Counsel on April 5, 2021. Ms. Cholapranee will report directly to Joe Burnett, ClearPoint Neuro\u2019s Chief Executive Officer, and serve as a member of the Company\u2019s senior leadership team. \u201cEllisa is a tremendous addition to our capable and growing leadership team,\u201d commented Joe Burnett, President and CEO of ClearPoint Neuro. \u201cNot only does Ellisa offer the broad experience in compliance, contracting and strategy, but like our Company itself, she has experience in both medical devices and biologics and drug delivery. Her insight &hellip; Continue reading \"ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-24T20:08:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTI3MiM0MDg4NTg0IzIwMjcxMjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel","datePublished":"2021-03-24T20:08:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/"},"wordCount":714,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTI3MiM0MDg4NTg0IzIwMjcxMjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/","name":"ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTI3MiM0MDg4NTg0IzIwMjcxMjA=","datePublished":"2021-03-24T20:08:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTI3MiM0MDg4NTg0IzIwMjcxMjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTI3MiM0MDg4NTg0IzIwMjcxMjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearpoint-neuro-inc-announces-appointment-of-ellisa-cholapranee-as-general-counsel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=464557"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464557\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=464557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=464557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=464557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}